Nicholas Sosiak

Cannara Biotech Inc. (TSXV:LOVE) (OTCQB:LOVFF) (FRA: 8CB0) announced its fiscal second quarter 2024 financial and operating results for the three and six-month periods ended Feb. 29, 2024. The company reported a 68% year-over-year increase in revenues for the first half of fiscal 2024, a metrics...

Cannara Biotech Inc. (OTCQB: LOVFF) (TSXV:LOVE) (FRA:8CB) has raised an additional $10 million of credit facilities from its lead bank, BMO Commercial Banking via a $5 million increase in its term loan facility and a $5 million increase in its revolving line of credit. Under the terms of the...

Cannara Biotech Inc. (OTCQB: LOVFF) (TSXV:LOVE) (FRA: 8CB) released its fiscal first quarter 2023 financial results for the three-month period ended November 30, 2022, revealing revenue of CA$10.3 million ($7.7 million), an 57% increase compared to Q1 2022. Q1 2023 Financial Highlights Gross...

Cannara Biotech Inc. (OTCQB: LOVFF) (TSXV:LOVE) (FRA:8CB), a Quebec-based, vertically integrated producer of cannabis and derivative product offerings, entered into the British Columbia (BC) market. In addition, the company launched two product offerings in the vape and accessory categories. "...

Cannara Biotech Inc. (OTCQB: LOVFF) (TSXV:LOVE) (FRA:8CB) has closed on a $50M credit facility led by BMO Commercial Banking. The credit facility, effective May 31, 2022, includes a three-year term loan for $45 million with an accordion for up to an additional $10 million and a $5 million line of...